TW491847B - Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one - Google Patents

Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one Download PDF

Info

Publication number
TW491847B
TW491847B TW086104173A TW86104173A TW491847B TW 491847 B TW491847 B TW 491847B TW 086104173 A TW086104173 A TW 086104173A TW 86104173 A TW86104173 A TW 86104173A TW 491847 B TW491847 B TW 491847B
Authority
TW
Taiwan
Prior art keywords
patent application
scope
dihydrate
mesylate
chloro
Prior art date
Application number
TW086104173A
Other languages
English (en)
Chinese (zh)
Inventor
Frank R Busch
Carol A Rose
Russell J Shine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of TW491847B publication Critical patent/TW491847B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
TW086104173A 1996-05-07 1997-04-01 Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one TW491847B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
TW491847B true TW491847B (en) 2002-06-21

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
TW086104173A TW491847B (en) 1996-05-07 1997-04-01 Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one

Country Status (40)

Country Link
US (1) US6245765B1 (enExample)
EP (1) EP0918772B1 (enExample)
JP (1) JP3494659B2 (enExample)
KR (1) KR100333215B1 (enExample)
CN (1) CN1091769C (enExample)
AP (1) AP765A (enExample)
AR (1) AR007004A1 (enExample)
AT (1) ATE278689T1 (enExample)
AU (1) AU731267B2 (enExample)
BG (1) BG63544B1 (enExample)
BR (1) BR9709889A (enExample)
CA (1) CA2252898C (enExample)
CO (1) CO4940466A1 (enExample)
CZ (1) CZ289215B6 (enExample)
DE (1) DE69731094T2 (enExample)
DK (1) DK0918772T3 (enExample)
DZ (1) DZ2222A1 (enExample)
EA (1) EA001190B1 (enExample)
EG (1) EG24076A (enExample)
ES (1) ES2229342T3 (enExample)
GT (1) GT199700052A (enExample)
HR (1) HRP970236B1 (enExample)
ID (1) ID16867A (enExample)
IL (1) IL126591A (enExample)
IS (1) IS2080B (enExample)
MA (1) MA24171A1 (enExample)
MY (1) MY119997A (enExample)
NO (1) NO312514B1 (enExample)
NZ (1) NZ332218A (enExample)
OA (1) OA10909A (enExample)
PL (1) PL188330B1 (enExample)
PT (1) PT918772E (enExample)
SI (1) SI0918772T1 (enExample)
SK (1) SK282837B6 (enExample)
TN (1) TNSN97074A1 (enExample)
TR (1) TR199802240T2 (enExample)
TW (1) TW491847B (enExample)
UA (1) UA46840C2 (enExample)
WO (1) WO1997042191A1 (enExample)
ZA (1) ZA973876B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
KR20030007824A (ko) * 2000-06-02 2003-01-23 화이자 프로덕츠 인크. 정신의학적 장애 및 안질환의 치료를 위한ｓ-메틸-디히드로-지프라시돈
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US7678799B2 (en) * 2003-06-03 2010-03-16 Teva Pharmaceutical Industries Ltd. Crystalline ziprasidone HCl and processes for preparation thereof
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
US20060258679A1 (en) * 2005-02-11 2006-11-16 Alex Mainfeld Process of preparing ziprasidone mesylate
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
US9469630B2 (en) * 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
TR199802241T2 (enExample) 1996-05-07 1999-02-22 Pfizer Inc.

Also Published As

Publication number Publication date
EP0918772A1 (en) 1999-06-02
AR007004A1 (es) 1999-10-13
DZ2222A1 (fr) 2002-12-03
PL188330B1 (pl) 2005-01-31
IS2080B (is) 2006-02-15
CN1216991A (zh) 1999-05-19
PL329884A1 (en) 1999-04-12
CZ349398A3 (cs) 1999-09-15
JPH11509867A (ja) 1999-08-31
NO985194L (no) 1998-11-06
CA2252898A1 (en) 1997-11-13
AU2174797A (en) 1997-11-26
EG24076A (en) 2008-05-11
MY119997A (en) 2005-08-30
EP0918772B1 (en) 2004-10-06
JP3494659B2 (ja) 2004-02-09
ES2229342T3 (es) 2005-04-16
SI0918772T1 (en) 2005-02-28
IS4874A (is) 1998-10-20
WO1997042191A1 (en) 1997-11-13
BG63544B1 (bg) 2002-04-30
ID16867A (id) 1997-11-20
KR20000010824A (ko) 2000-02-25
BR9709889A (pt) 1999-08-10
IL126591A (en) 2001-11-25
PT918772E (pt) 2004-12-31
TR199802240T2 (enExample) 1999-02-22
EA001190B1 (ru) 2000-12-25
DK0918772T3 (da) 2005-01-10
BG102892A (en) 1999-09-30
US6245765B1 (en) 2001-06-12
AU731267B2 (en) 2001-03-29
NO312514B1 (no) 2002-05-21
HK1017892A1 (en) 1999-12-03
MA24171A1 (fr) 1997-12-31
CN1091769C (zh) 2002-10-02
ATE278689T1 (de) 2004-10-15
CA2252898C (en) 2003-04-08
UA46840C2 (uk) 2002-06-17
OA10909A (en) 2001-10-26
AP9700976A0 (en) 1997-07-31
KR100333215B1 (ko) 2002-06-20
IL126591A0 (en) 1999-08-17
HRP970236B1 (en) 2002-12-31
CO4940466A1 (es) 2000-07-24
CZ289215B6 (cs) 2001-12-12
SK150898A3 (en) 2000-02-14
NO985194D0 (no) 1998-11-06
HRP970236A2 (en) 1998-06-30
AP765A (en) 1999-09-17
NZ332218A (en) 2005-02-25
GT199700052A (es) 2001-08-29
TNSN97074A1 (fr) 2005-03-15
SK282837B6 (sk) 2002-12-03
DE69731094T2 (de) 2006-02-23
DE69731094D1 (de) 2004-11-11
EA199800912A1 (ru) 1999-04-29
ZA973876B (en) 1998-11-06

Similar Documents

Publication Publication Date Title
JP2742372B2 (ja) ５−（２−（４−（１，２−ベンゾイソチアゾール−３−イル）−１−ピペラジニル）エチル）−６−クロロ−１，３−ジヒドロ−２ｈ−インドール−２−オン塩酸塩の一水和物
AU731267B2 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzis othiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2 (1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
TW513432B (en) 2-methyl-thieno-benzodiazepine polymorph and its process for preparation and use
AP838A (en) Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one.
JP2023175689A (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
WO2020221272A1 (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
JP3199736B2 (ja) アミノアルキル置換された２−アミノ−５−メルカプトチアジアゾール、その製造及び使用
US6962924B2 (en) Salt and polymorphs of desloratadine hemifumarate
CN101203500B (zh) 取代的芳胺化合物和它们作为5-ht6调节剂的用途
HUP9902404A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(2H)-indol-2-on (ziprazidon) mezilát-dihidrát sói, a vegyületek előállitása és dopamin D2 antagonistaként történő alkalmazása
MXPA98009242A (en) Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2-

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees